C., & Siegelaar, S
Every batch is HPLC-tested to confirm a purity of 99%, consistent with its GLP-1/GIP/GCGR triple-agonist profile (CAS number 2381089-83-2)
Patients also experienced a 13 cm reduction in waist line, more than 5 point reduction in BMI, and overall reductions in blood pressure, glycated hemoglobin (A1C), C-reactive protein, and cholesterol levels
As of December 2025, there are no peer-reviewed trials directly examining whether a GLP-1 agonist helps or harms exercise performance in athletes
Table 14: Lipid-Modifying Effects of Rosuvastatin in Pediatric Patients 7 to 15 years of Age with HoFH After 6 Weeks % Difference estimates are based on transformations of the estimated mean difference in log LDL measurements between rosuvastatin and placebo using a mixed model adjusted for study period 1p=0.005, 2 p=0.003, 3 p=0.024 Primary Dysbetalipoproteinemia in Adults In a randomized, multicenter, double-blind cross-over study, 32 adult patients (27 with 2/2 and 4 with apo E mutation [Arg145Cys] with primary dysbetalipoproteinemia entered a 6-week dietary lead-in period on the NCEP Therapeutic Lifestyle Change (TLC) diet